Swedish biotech venture LIDDS AB has received approval from the Danish Medicines Agency (DKMA) to conduct a Phase I trial--NZ-DTX-001. This is in addition to a study already approved in Sweden at the Karolinska University Hospital.  The aim of the trial is to assess...